Item 7.01 Regulation FD Disclosure
On
The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Item 8.01 Other Events
On
Under the terms of the collaboration, Twist will leverage its proprietary single
chain fragment variable (scFv) and VHH (nanobody) technologies from its
The disclosure under this Item 8.01 contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995 relating to
business and operations of Adicet including, but not limited to, express or
implied statements regarding the potential benefits resulting from the
collaboration with Twist to Adicet's business or strategy, including Adicet's
ability to rapidly identify and optimize unique antibodies and related
target-engagement technologies to facilitate Adicet's CAR pipeline, the payment
of upfront license fees and potential milestone and royalty payments under the
collaboration, the expected potential therapeutic effects of Adicet's product
candidates, and expectations regarding the timing and success of preclinical and
clinical development of Adicet's product candidates, including in connection
with the collaboration. Any forward-looking statements in the disclosure under
this Item 8.01 are based on management's current expectations and beliefs of
future events, and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those set forth in
or implied by such forward-looking statements, including without limitation, the
effect of COVID-19 on Adicet's business and financial results, including with
respect to disruptions to its clinical trials and business operations; future
clinical studies may fail to demonstrate adequate safety and efficacy of
Adicet's product candidates, which would prevent, delay, or limit the scope of
regulatory approval and commercialization; regulatory approval processes of the
FDA and comparable foreign regulatory authorities are lengthy, time-consuming,
and inherently unpredictable; as well as those risks and uncertainties set forth
in Adicet's most recent annual report on Form 10-K and subsequent filings with
the
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit Number Description 99.1 Press release issued byAdicet Bio, Inc. onSeptember 13, 2021 , furnished herewith. 104 Cover Page Interactive Data File
--------------------------------------------------------------------------------
© Edgar Online, source